Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
Gottlieb AB, Griffiths CE, Ho VC, Lahfa M, Mrowietz U, Murrell DF, Ortonne JP, Todd G, Cherill R, Marks I, Emady-Azar S, Paul CF; Multi-Centre Investigator Group. Gottlieb AB, et al. Among authors: paul cf. Br J Dermatol. 2005 Jun;152(6):1219-27. doi: 10.1111/j.1365-2133.2005.06661.x. Br J Dermatol. 2005. PMID: 15948985 Clinical Trial.
Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial.
Wolff K, Fleming C, Hanifin J, Papp K, Reitamo S, Rustin M, Shear N, Silny W, Korman N, Marks I, Cherill R, Emady-Azar S, Paul C; Multicentre Investigator Group. Wolff K, et al. Among authors: paul c. Br J Dermatol. 2005 Jun;152(6):1296-303. doi: 10.1111/j.1365-2133.2005.06674.x. Br J Dermatol. 2005. PMID: 15948996 Clinical Trial.
Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France.
Maza A, Richard MA, Aubin F, Ortonne JP, Prey S, Bachelez H, Beylot-Barry M, Bulai-Livideanu C, Lahfa M, Nougué J, Mengual X, Le Moigne M, Lauwers-Cances V, Paul C. Maza A, et al. Among authors: paul c. Br J Dermatol. 2012 Sep;167(3):643-8. doi: 10.1111/j.1365-2133.2012.10991.x. Epub 2012 Jul 5. Br J Dermatol. 2012. PMID: 22512545
Psoriasis: rationale for targeting interleukin-17.
Girolomoni G, Mrowietz U, Paul C. Girolomoni G, et al. Among authors: paul c. Br J Dermatol. 2012 Oct;167(4):717-24. doi: 10.1111/j.1365-2133.2012.11099.x. Br J Dermatol. 2012. PMID: 22716185 Review.
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mistry S, Bergmans P, Barker J; TRANSIT Investigators. Reich K, et al. Among authors: paul c. Br J Dermatol. 2014 Feb;170(2):435-44. doi: 10.1111/bjd.12643. Br J Dermatol. 2014. PMID: 24116868 Clinical Trial.
2,136 results